Trial · NCT05328154
Registered outcomes60
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 60
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | C-terminal telopeptides of collagen type 1 (CTX) dosage | Visit 0: Day 0-1 month | Evaluation of the CTX evolution after one year, defined as the difference \[after - before\], relative to the basal value (ng/ml). For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Primary | C-terminal telopeptides of collagen type 1 (CTX) dosage | Visit 3: Day 0+1 year | Evaluation of the CTX evolution after one year, defined as the difference \[after - before\], relative to the basal value (ng/ml). For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | N-terminal propeptide of procollagen type 1 (P1NP) dosage | Visit 1: Day 0 | The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | N-terminal propeptide of procollagen type 1 (P1NP) dosage | Visit 3: Day 0+1 year | The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Osteocalcin dosage | Visit 1: Day 0 | The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes |
| Secondary | Osteocalcin dosage | Visit 3: Day 0+1 year | The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes |
| Secondary | Sclerostin dosage | Visit 1: Day 0 | The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Sclerostin dosage | Visit 3: Day 0+1 year | The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Periostin dosage | Visit 1: Day 0 | The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Periostin dosage | Visit 3: Day 0+1 year | The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Irisin dosage | Visit 1: Day 0 | The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage. |
| Secondary | Irisin dosage | Visit 3: Day 0+1 year | The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage. |
| Secondary | Dickkopf-related protein 1 (DKK1) dosage | Visit 1: Day 0 | The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Dickkopf-related protein 1 (DKK1) dosage | Visit 3: Day 0+1 year | The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes. |
| Secondary | Magnesium (Mg) dosage | Visit 1: Day 0 | A blood sample will be taken using 3 mL lithium heparin tube for the dosage of the magnesium (mmol/L). |
| Secondary | Magnesium (Mg) dosage | Visit 2: Day 0+9 months | A blood sample will be taken using 3 mL lithium heparin tube for the dosage of the magnesium (mmol/L). |
| Secondary | Magnesium (Mg) dosage | Visit 3: Day 0+1 year | A blood sample will be taken using 3 mL lithium heparin tube for the dosage of the magnesium (mmol/L). |
| Secondary | Evaluation of bone densitometric parameters (femoral neck) | Visit 0: Day 0-1 month | Densitometry analysis on the three usual sites (femoral neck) by Dual X-ray Absorptiometry (DXA). T-scores will be analyzed at these sites, as well as densitometry in grams per square centimeter. |
| Secondary | Evaluation of bone densitometric parameters (femoral neck) | Visit 3: Day 0+1 year | Densitometry analysis on the three usual sites (femoral neck) by Dual X-ray Absorptiometry (DXA). T-scores will be analyzed at these sites, as well as densitometry in grams per square centimeter. |
| Secondary | Evaluation of bone densitometric parameters (total femur) | Visit 0: Day 0-1 month | Densitometry analysis on the three usual sites (total femur) by Dual X-ray Absorptiometry (DXA). T-scores will be analyzed at these sites, as well as densitometry in grams per square centimeter. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05328154/registered